focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: Hargreaves Lansdown Hit After Profit Drop

Wed, 04th Feb 2015 11:40

LONDON (Alliance News) - The following stocks are amongst the biggest risers and fallers within the main London indices midday Wednesday.
-------
FTSE 100 WINNERS
-------
Sky, up 1.9%. The company posted a big increase in pretax profit for the first half of its financial year, boosted by a rise in revenue and exceptional gains from the sale of its stakes in ITV PLC and the National Geographic Channel. Profit was boosted by a GBP492 million gain from the sale of its 6.4% stake in ITV PLC and a GBP296 million gain from the sale of its stake in the National Geographic Channel.

Arm Holdings, up 1.6%. The chip designer announced a new suite of intellectual properties that are expected to be launched on mobile devices in 2016, including its ARM Cortex-A72 processor. The group said that in target configurations, the new processor well deliver CPU performance that is 50 times that of leading smartphones from five years ago.

Antofagasta, up 1%, Rio Tinto, up 0.4%, Glencore, up 0.4%, Fresnillo, up 1.3%, and Randgold Resources, up 0.5%, Mining shares are up after China's central bank lowered its banks' reserve requirement ratio by 0.5 percentage points in order to support lending. The gold miners are  getting a boost from a rise in the gold price to USD1,268.86.

GlaxoSmithKline, up 0.3%. Sky News reported that it has learnt that Glaxo has hired Citi, Goldman Sachs and Morgan Stanley as financial advisers on its HIV medicines joint venture ViiV Healthcare. It says the appointment of the banks will fuel the prospect of Glaxo floating the division, which analysts believe could be worth at least GBP17 billion. The shares are up ahead of the company's full year results at 1200 GMT.
-------
FTSE 100 LOSERS
-------
Hargreaves Lansdown, down 5.7%. The investment management product provider reported a drop in first-half pretax profit, despite a rise in assets under administration over the course of the six months, in what was described as a "muted" time for stocks and retail investors. The group said pretax profit declined to GBP101.9 million in the six months ended December 31 from GBP104.1 million in the corresponding period last year.

Tullow Oil, down 3.9%, BP, down 1.5% and Weir Group, down 1.4%. A drop in oil prices is dragging down oil-related stocks. Brent currently trades at USD56.44 a barrel. Moreover, Royal Dutch Shell B, down 1.9%, and Royal Shell A, down 1.5%, has suffered price target cuts. Liberum has cut the oil major price target to 2,120p from 2,230p, keeping its rating at Hold, while LBBW has cut the company's price target price target to 2,450p from 2,600p, keeping its rating at Buy.
-------
FTSE 250 WINNERS
-------
BTG, up 1.4%. Panmure has raised the Healthcare company's price target to 1,305p from 800p, keeping its rating at Buy.
-------
FTSE 250 LOSERS
-------
Afren, down 7.5% and Premier Oil, down 2.5%. Both oil-related stocks are suffering from the fall in oil prices.

Moneysupermarket.com Group, down 3.9%. Numis said the stock is overvalued against its online listed peers, based on numerous metrics, and the broker would be downbeat on the company at its current share price even without the potential threat posed by Google
-------
AIM ALL-SHARE WINNERS
-------
Camkids Group, up 38%. The China-based children's clothing company shares are up, even though it said it expects its results for the year to miss market expectations after a number of orders were cancelled in December, exacerbating existing problems the company was facing from the weaker economic environment in China. Following that warning, certain distributors for Camkids requested the postponement or cancellation of some orders totalling CNY79 million. The company said it thought its shares were being undervalued.

Dillistone Group, up 19%. Recruitment software supplier said it expects its full year results for 2014, excluding acquisition related items, will be at a similar level to 2013, and said it enters 2015 with a stronger pipeline. The company said order intake in its Systems Division rose more than 20% in the fourth quarter of 2014. It said it had won more new business contracts in December than it had in any month of the last two years.

Nostra Terra Oil and Gas Co, up 8.7%. The company said it placed four new wells into production during the fourth quarter which significantly increased production and said although its partners are cutting back on drilling activity, it will take advantage of the low oil price to try and secure further growth opportunities.

Mosman Oil and Gas, up 6.9%. The group said it has started flow testing on the Crossroads-1 well at its Petroleum Creek project in New Zealand and it has now received the technical report on the cores and cuttings from the 2014 drilling programme at Crestal-1 and Crestal-2.
-------
AIM ALL-SHARE LOSERS
-------
Craven House Capital, off 8%. Investment company said that talks over a potential investment have ended, after it had confirmed last month that talks were ongoing. "The company confirms that these discussions have been terminated," Craven House Capital said.
-------

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.